Relapse localization in Danish pediatric patients with Hodgkin lymphoma

References

• Schellong G, Brämswig J, Ludwig R, et al. Kombinierte Behandlungsstrategie bei über 200 Kindern mit Morbus Hodgkin: Abgestufte Chemotherapie, Involved-Field-Bestrahlung mit erniedrigten Dosen und selektive Splenektomie. Ein Bericht Der Kooperativen Therapiestudie DAL-HD-82*. Klin Pädiatrie. 1986;198:137–146.
   PubMed Web of Science ®Google Scholar
• Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood. 2011;117(9):2596–2603.
   PubMed Web of Science ®Google Scholar
• Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806–1816.
   PubMed Web of Science ®Google Scholar
• Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin’s lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol. 2016;17(9):1325–1334.
   PubMed Web of Science ®Google Scholar
• Veiga LH, Curtis RE, Morton LM, et al. Association of breast cancer risk after childhood cancer with radiation dose to the breast and anthracycline use. JAMA Pediatr. 2019;173(12):1171.
   Web of Science ®Google Scholar
• Dörffel W, Rühl U, Lüders H, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol. 2013;31(12):1562–1568.
   PubMed Web of Science ®Google Scholar
• Mauz-Körholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28(23):3680–3686.
   PubMed Web of Science ®Google Scholar
• Wolden SL, Chen L, Kelly KM, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma-a report from the Children's Oncology Group. J Clin Oncol. 2012;30(26):3174–3180.
   PubMed Web of Science ®Google Scholar
• Metzger ML, Weinstein HJ, Hudson MM, et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012;307(24):2609–2616.
   PubMed Web of Science ®Google Scholar
• Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children’s Oncology Group Study AHOD0031. J Clin Oncol. 2014;32(32):3651–3658.
   PubMed Web of Science ®Google Scholar
• Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group . Br J Haematol. 2019;187(1):39–48.
   PubMed Web of Science ®Google Scholar
• Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer. 1997;33(6):848–853.
   PubMed Web of Science ®Google Scholar
• Charpentier A-M, Friedman DL, Wolden S, et al. Predictive factor analysis of response-adapted radiation therapy for chemotherapy-sensitive pediatric hodgkin lymphoma: analysis of the Children's Oncology Group AHOD 0031 Trial. Int J Radiat Oncol Biol Phys. 2016;96(5):943–950.
   PubMed Web of Science ®Google Scholar
• Dieckmann K, Pötter R, Hofmann J, et al. Does bulky disease at diagnosis influence outcome in childhood Hodgkin’s disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. Int J Radiat Oncol Biol Phys. 2003;56(3):644–652.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 2014;32(27):3059–3067.
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–862.
   PubMed Web of Science ®Google Scholar
• Krasin MJ, Rai SN, Kun LE, et al. Patterns of treatment failure in pediatric and young adult patients with Hodgkin's disease: local disease control with combined-modality therapy. J Clin Oncol. 2005;23(33):8406–8413.
   PubMed Web of Science ®Google Scholar
• Dhakal S, Biswas T, Liesveld JL, et al. Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2009;75(1):188–192.
   PubMed Web of Science ®Google Scholar
• Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children’s Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):60–66.
   PubMed Web of Science ®Google Scholar
• Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol. 2004;22(22):4541–4550.
   PubMed Web of Science ®Google Scholar
• Keller FG, Castellino SM, Chen L, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children's Oncology Group. Cancer. 2018;124(15):3210–3219.
   PubMed Web of Science ®Google Scholar
• André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017;35(16):1786–1794.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598–1607.
   PubMed Web of Science ®Google Scholar
• Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol. 2019;37(31):2835–2845.
   PubMed Web of Science ®Google Scholar
• Nielsen K, Maraldo MV, Berthelsen AK, et al. Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: analysis of relapse location and long-term outcome. Radiother Oncol. 2020;150:236–244.
   PubMed Web of Science ®Google Scholar
• Englund A, Glimelius I, Rostgaard K, et al. Hodgkin lymphoma in children, adolescents and young adults–a comparative study of clinical presentation and treatment outcome. Acta Oncol. 2018;57(2):276–282.
   PubMed Web of Science ®Google Scholar
• Specht L. Radiotherapy for Hodgkin lymphoma: reducing toxicity while maintaining efficacy. Cancer J. 2018;24(5):237–243.
   PubMed Web of Science ®Google Scholar
• Mottok A, Steidl C. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood. 2018;131(15):1654–1665.
   PubMed Web of Science ®Google Scholar
• Schellong G, Dörffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol. 2005;23(25):6181–6189.
   PubMed Web of Science ®Google Scholar
• Rimner A, Lovie S, Hsu M, et al. Accelerated Total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma: 20 years of experience. Int J Radiat Oncol Biol Phys. 2017;97(5):1066–1076.
   PubMed Web of Science ®Google Scholar
• Jhawar SR, Rivera-Núñez Z, Drachtman R, et al. Association of combined modality therapy vs chemotherapy alone with overall survival in early-stage pediatric Hodgkin lymphoma. JAMA Oncol. 2019;5(5):689.
   PubMed Web of Science ®Google Scholar